Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation

Clin Biochem. 2010 Apr;43(6):559-65. doi: 10.1016/j.clinbiochem.2010.01.003. Epub 2010 Jan 18.

Abstract

Objectives: Little is known about the influence of calcineurin inhibitors on advanced oxidation protein products (AOPP) and total antioxidant status (TAS) after renal transplantation.

Design and methods: AOPP and TAS were evaluated in transplanted patients on different calcineurin inhibitors. Thirty-five patients were treated with cyclosporine A (group A) and 33 with tacrolimus (group B).

Results: Over 6 months, the mean levels of AOPP in group A decreased from 205.9+/-125.7 to 140.9+/-78.9 micromol/L and TAS from 1.89+/-0.30 to 1.75+/-0.27 mmol/L. In group B, the mean levels of AOPP decreased from 196.5+/-123.9 to 129.6+/-63.8 micromol/L and TAS from 1.80+/-0.39 to 1.78+/-0.23 mmol/L.

Conclusion: No significant differences in AOPP and TAS were found with respect to treatment. The only exception was the higher mean concentration of AOPP at month 1 in group A (p=0.026).

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antioxidants / metabolism*
  • Calcineurin Inhibitors*
  • Cyclosporine / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / rehabilitation
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation* / rehabilitation
  • Male
  • Middle Aged
  • Oxidative Stress / drug effects*
  • Proteins / metabolism*
  • Tacrolimus / pharmacology

Substances

  • Antioxidants
  • Calcineurin Inhibitors
  • Enzyme Inhibitors
  • Proteins
  • Cyclosporine
  • Tacrolimus